<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568046</url>
  </required_header>
  <id_info>
    <org_study_id>Sym004-09</org_study_id>
    <secondary_id>2015-003047-19</secondary_id>
    <nct_id>NCT02568046</nct_id>
  </id_info>
  <brief_title>Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients</brief_title>
  <official_title>An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symphogen A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Symphogen A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2a study investigating the safety and effect of Sym004 in combination with
      FOLFIRI (chemotherapy) when administered every second week.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase 1b (dose-escalation) portion of the trial is expected to begin Q1 2016. Patients
      will be sequentially enrolled to dose-escalation cohorts until establishment of the Maximum
      Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of Sym004 in combination with
      FOLFIRI.

      The phase 2a (dose-expansion) portion of the trial is expected to begin after establishing
      the RP2D.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Assess the safety and tolerability of Sym004 in combination with FOLFIRI</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the occurrence of dose-limiting toxicities (DLT) during Cycle 1 of Sym004 administration in combination with FOLFIRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a: Evaluate the antitumor activity of Sym004 in combination with FOLFIRI</measure>
    <time_frame>1 year</time_frame>
    <description>Documented objective response (OR) (defined as partial response [PR] or complete response [CR]), assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events (AEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.03</measure>
    <time_frame>2 Years</time_frame>
    <description>Nature, incidence, and severity of AEs measured from baseline to end of trial participation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of OR from time of first PR or CR to progressive disease (PD) as assessed by RECIST v1.1</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Dose-normalized area under the concentration-time curve from End of Infusion (EOI) to 336 hours (AUCNorm, 0-336h)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Area under the concentration-time curve from EOI to 336 hours (AUC0-336h)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Maximum concentration (Cmax)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be derived from observed data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Time to reach maximum concentration (Tmax)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be derived from observed data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Trough concentration (Ctrough)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be derived from observed data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Elimination half-life (TÂ½)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Clearance (CL)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Volume of distribution (V)</measure>
    <time_frame>1 Year</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Sym004 + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b, dose-escalation:
Dose Level 1: Sym004 12 mg/kg + FOLFIRI (Q2W)
Dose Level 2: Sym004 15 mg/kg + FOLFIRI (Q2W)
Dose Level 3: Sym004 18 mg/kg + FOLFIRI (Q2W)
If the toxicity profile of Dose Level 1 indicates that this dose is not tolerated, successive lower dose levels will be explored:
Dose Level -1: Sym004 9 mg/kg + FOLFIRI
Dose Level -2: Sym004 9 mg/kg (loading dose) + FOLFIRI, followed by 6 mg/kg + FOLFIRI
Dose Level -3: Sym004 6 mg/kg + FOLFIRI
FOLFIRI regimen consists of Irinotecan, Folinic Acid, and Fluorouracil (5-FU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym004 (RP2D) + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2a, dose-expansion:
Receiving Sym004 in the RP2D in combination with FOLFIRI
FOLFIRI regimen consists of Irinotecan, Folinic Acid, and Fluorouracil (5-FU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym004</intervention_name>
    <description>The Investigational Medicinal Product (IMP) is Sym004. Sym004 is a 1:1 mixture of 2 monoclonal Antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).</description>
    <arm_group_label>Sym004 + FOLFIRI</arm_group_label>
    <arm_group_label>Sym004 (RP2D) + FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m2 iv, infused over 60-90 minutes</description>
    <arm_group_label>Sym004 + FOLFIRI</arm_group_label>
    <arm_group_label>Sym004 (RP2D) + FOLFIRI</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400 mg/m2 iv, infused over 120 minutes concurrently with Irinotecan</description>
    <arm_group_label>Sym004 + FOLFIRI</arm_group_label>
    <arm_group_label>Sym004 (RP2D) + FOLFIRI</arm_group_label>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>After the Irinotecan and Folinic Acid infusions, Fluorouracil (5-FU) 400 mg/m2 iv bolus, then 2400 mg/m2 5-FU infused over 46 hours</description>
    <arm_group_label>Sym004 + FOLFIRI</arm_group_label>
    <arm_group_label>Sym004 (RP2D) + FOLFIRI</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          1. Male or female, at least 18 years of age at the time of informed consent

          2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          3. Histologically or cytologically confirmed, locally advanced or metastatic colorectal
             cancer (CRC) that is documented to be without Kirsten rat sarcoma (KRAS) or
             Neuroblastoma rat sarcoma (NRAS) gene mutations (i.e. tumors must express the KRAS and
             NRAS wild type (WT), exon 2, 3 and 4).

          4. Failed* treatment for locally advanced or metastatic disease with first-line
             combination therapy of oxaliplatin and a fluoropyrimidine, with or without
             bevacizumab, during treatment or &lt; 3 months after the last dose of first-line therapy
             and within &lt; 3 months of C1/D1.

             Patients who discontinued first-line therapy due to toxicity may be enrolled provided
             progression occurred &lt; 6 months after the last dose of the first-line therapy regimen.

             or Failed* adjuvant therapy with combination therapy of oxaliplatin and a
             fluoropyrimidine during treatment or within &lt; 6 months after the last dose of
             oxaliplatin and within &lt; 6 months of C1/D1.

               -  Failure is defined as radiologic progression

          5. Eligible for FOLFIRI

          6. Measurable disease according to RECIST v1.1

        Main exclusion Criteria:

          1. Prior therapy with anti-EGFR antibodies, anti-EGFR small molecule inhibitors or
             irinotecan (CPT-11)

          2. Any antineoplastic agent (standard or investigational) within 4 weeks prior to C1/D1

          3. Significant gastrointestinal abnormalities

          4. Patients with a significant cardiovascular disease or condition

          5. Abnormal hematologic, renal or hepatic function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Tabernero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hosptal</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Not yet decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

